Assessment of incidence of inhibitors in patients with haemophilia

被引：8

作者：

Van Der Bom, J. G. ^{[1
,2
]}

Ter Avest, P. ^{[3
]}

Van Den Berg, H. M. ^{[3
]}

Psaty, B. M. ^{[4
,5
,6
]}

Weiss, N. S. ^{[4
,5
]}

机构：

[1] Leiden Univ, Dept Clin Epidemiol, Med Ctr, NL-2300 RC Leiden, Netherlands

[2] Leiden Univ, Einthoven Lab Expt Vasc Med, Med Ctr, NL-2300 RC Leiden, Netherlands

[3] Univ Utrecht, Lab Ctr, Med Ctr, Utrecht, Netherlands

[4] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA

[5] Univ Washington, Dept Med & Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA

[6] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, GrpHlth, Seattle, WA 98101 USA

来源：

HAEMOPHILIA | 2009年 / 15卷 / 03期

关键词：

inhibitory; risk; selection; RECOMBINANT FACTOR-VIII; PREVIOUSLY UNTREATED PATIENTS; PREVIOUSLY TREATED PATIENTS; FACTOR-IX INHIBITORS; MULTITRANSFUSED HEMOPHILIA; CLINICAL-EVALUATION; HOME THERAPY; RISK-FACTORS; LONG-TERM; MULTICENTER;

D O I：

10.1111/j.1365-2516.2009.02002.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In patients with haemophilia, the development of neutralizing allo-antibodies ('inhibitors') while receiving the deficient clotting factor is relatively common during the patients' initial treatment. Among treated patients with haemophilia who do not develop inhibitors early on, the later incidence is considerably lower. Therefore, the evaluation of potential risk factors for their tendency to give rise to inhibitors is best performed separately in previously untreated and previously treated patients. We discuss potential implications of study design and analysis choices on the validity of inferences from studies assessing inhibitor incidences.

引用

页码：707 / 711

页数：5

共 35 条

[1]

Abshire TC, 2000, THROMB HAEMOSTASIS, V83, P811

[2] Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A [J].

Astermark, J. ;

Wang, X. ;

Oldenburg, J. ;

Berntorp, E. ;

Lefvert, A. -K. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (02) :263-265

[3] Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A [J].

Astermark, J ;

Oldenburg, J ;

Pavlova, A ;

Berntorp, E ;

Lefvert, AK .

BLOOD, 2006, 107 (08) :3167-3172

[4] The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development [J].

Astermark, J ;

Berntorp, E ;

White, GC ;

Kroner, BL .

HAEMOPHILIA, 2001, 7 (03) :267-272

[5]

BRIET E, 1994, THROMB HAEMOSTASIS, V72, P162

[6] Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A [J].

Chalmers, E. A. ;

Brown, S. A. ;

Keeling, D. ;

Liesner, R. ;

Richards, M. ;

Stirling, D. ;

Thomas, A. ;

Vidler, V. ;

Williams, M. D. ;

Young, D. .

HAEMOPHILIA, 2007, 13 (02) :149-155

[7]

*COMM MED PROD HUM, 2008, CONC PAP REV NOT GUI

[8] Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients [J].

Courter, SG ;

Bedrosian, CL .

SEMINARS IN HEMATOLOGY, 2001, 38 (02) :52-59

[9] The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99 [J].

Darby, SC ;

Keeling, DM ;

Spooner, RJD ;

Kan, SW ;

Giangrande, PLF ;

Collins, PW ;

Hill, FGH ;

Hay, CRM .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (07) :1047-1054

[10] INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS [J].

EHRENFORTH, S ;

KREUZ, W ;

SCHARRER, I ;

LINDE, R ;

FUNK, M ;

GUNGOR, T ;

KRACKHARDT, B ;

KORNHUBER, B .

LANCET, 1992, 339 (8793) :594-598

← 1 2 3 4 →